Skip to main content

Search
Profile

Ron Gibson, MD, PhD

|
Ron Gibson, MD, PhD

Pulmonary and Sleep Medicine, Cystic Fibrosis Research

On staff since November 1987

Children's Title: Director, Cystic Fibrosis Center; Co-Director, Cystic Fibrosis Therapeutic Development Center; Director, Pediatric Pulmonary Fellowship

Academic Title: Professor

Research Center: Center for Clinical and Translational Research

Overview

Board Certification(s)
Pediatrics
Pediatric Pulmonology
Medical/Professional School
Washington University School of Medicine, St Louis
Residency
Pediatrics, University of Washington, Seattle
Fellowship
Pulmonary Disease, University of Washington, Seattle
Research Focus Area

Cystic Fibrosis

Awards and Honors

Award NameAward DescriptionAwarded ByAward Date
SEATTLE MAGAZINE TOP DOCTOR - 2014Seattle Magazine 2014
SEATTLE'S TOP DOCTOR - 2014Seattle Metropolitan Magazine 2014
Seattle Magazine Top Doctor - 2013Seattle Magazine 2013
Seattle's Top DocSeattle Met Magazine 2013
Seattle Magazine Top Doctor - 2012Seattle Magazine Top Doctor - 2012Seattle Magazine 2012
U.S. News Top DoctorU.S. News and World Report 2012
Seattles Top DoctorsSeattle Magazine 2011
Seattles Top DoctorsSeattle Magazine 2010
Nominee, Family Choice Award from Family Advisory CouncilSeattle Children's Hospital 2009
"Guide to America's Top Pediatricians"Consumer's Research Council of America 2009
Mentoring Award from the University of Washington School of MedicineDepartment of Pediatrics , University of Washington 2008
Selected to Best Doctors in AmericaBest Doctors in America 2007 - 2009

Publications

Home Self-Collection of Nasal Swabs for Diagnosis of Acute Respiratory Virus Infections in Children With Cystic Fibrosis.
Journal of the Pediatric Infectious Diseases Society , 2013 Dec: 2(4)345-351
Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.
Pediatric pulmonology , 2013 Oct: 48(10)943-53
Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.
Pediatric pulmonology , 2013 Oct: 48(10)943-53
Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections.
American journal of human genetics , 2013 Aug 8: 93(2)398-404
Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America , 2013 Aug: 57(3)384-91
Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy.
Circulation. Cardiovascular genetics , 2013 Apr: 6(2)144-53
Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants.
Nature , 2013 Jan 10: 493(7431)216-20
Fine-scale patterns of population stratification confound rare variant association tests.
PloS one , 2013: 8(7)e65834
Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2012 Sep: 11(5)456-7
Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2012 Sep: 11(5)446-53
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2012 Aug 31
Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Nature genetics , 2012 Jul 8: 44(8)886-9
Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings.
Influenza and other respiratory viruses , 2012 May: 6(3)218-23
Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2012 May: 11(3)216-22
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
Pediatric pulmonology , 2012 Feb: 47(2)125-34
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
Pediatric pulmonology , 2012 Feb: 47(2)125-34
Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
The Journal of antimicrobial chemotherapy , 2011 Oct: 66(10)2398-404
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
Archives of pediatrics & adolescent medicine , 2011 Sep: 165(9)847-56
Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2011 Jul: 10(4)234-42
Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.
Pediatric pulmonology , 2011 Feb: 46(2)184-92
An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.
Pediatric pulmonology , 2010 Nov: 45(11)1121-34
Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.
Pediatric pulmonology , 2010 Sep: 45(9)934-44
Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
Pediatric pulmonology , 2010 Feb: 45(2)127-34
Genetic modifiers of liver disease in cystic fibrosis.
JAMA : the journal of the American Medical Association , 2009 Sep 9: 302(10)1076-83
Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
Chest , 2009 May: 135(5)1223-32
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Contemporary clinical trials , 2009 May: 30(3)256-68
Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
The Journal of pediatrics , 2009 Feb: 154(2)183-8
Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.
Genetics in medicine : official journal of the American College of Medical Genetics , 2008 Dec: 10(12)851-68
Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
American journal of respiratory and critical care medicine , 2008 Nov 1: 178(9)921-8
A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
Pediatric pulmonology , 2008 Jan: 43(1)47-58
Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
Pediatric pulmonology , 2007 Sep: 751-6
Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
Pediatric pulmonology , 2007 Sep: 42(9)751-6
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
American journal of respiratory cell and molecular biology , 2007 Jul: 57-66
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
American journal of respiratory cell and molecular biology , 2007 Jul: 37(1)57-66
Disease-specific reference equations for lung function in patients with cystic fibrosis.
American journal of respiratory and critical care medicine , 2005 Oct 1: 885-91
Disease-specific reference equations for lung function in patients with cystic fibrosis.
American journal of respiratory and critical care medicine , 2005 Oct 1: 172(7)885-91
Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
Pediatric pulmonology , 2005 Apr: 339-48
Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
Pediatric pulmonology , 2005 Apr: 39(4)339-48
Abstracts - Available upon request
,

Presentations

Presentations TitleEventLocationDate
Comparison of exome variants from phenotype extremes to a large population-based sample identifies CAV2 and TMC6 as interacting modifiers of chronic Pseudomonas infection in cystic fibrosisNorth American Cystic Fibrosis ConferenceSalt Lake City, Utah 2013

Research Funding

Grant TitleGrantorAmountAward Date
Cystic Fibrosis Bronchoalveolar Lavage Fluid Specimen BankCystic Fibrosis Foundation
Role of Islet Amyloid and IL-1 Signaling in -cell Loss in Cystic Fibrosis Related DiabetesNIH
An Open-Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in Subjects with Cystic Fibrosis (VX08-770-105)Vertex
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects with Cystic Fibrosis Who Have the R117H-CFTR Mutation (VX11-770-110)Vertex
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (VX12-809-103Vertex
A Phase 3, Blinded, Rollover Study to Evaluate the Safety and Efficacy of Long-Term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (VX12-809-105)Vertex
Comparison study of regulatory T cell phenotypes and function in blood samples from individuals with CF and healthy non-CF controlsCystic Fibrosis Foundation
The EPIC Observational Study: Longitudinal Assessment of Risk Factors and Impact of Pseudomonas aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF (Protocol # EPIC-002)Cystic Fibrosis Foundation $, $
CF EPIC Participation in the NHLBI Lung Cohorts Sequencing ProjectNIH
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)NIH
Director, Clinical Core, Cystic Fibrosis Research Development ProgramCystic Fibrosis Foundation
Co-director, Clinical Core, P30 Translational Research Center to Expedite Novel Therapies in Cystic FibrosisNIH
Cystic Fibrosis Foundation National Patient RegistryCystic Fibrosis Foundation
Early Intervention in CF ExacerbationNIH
I Change Adherence and Raise ExpectationsNovartis
A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) Versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis PatientsMPex
Early MRSA Therapy in CF- culture based vs observant therapy (treat or observe) (STAR-too)Cystic Fibrosis Foundation

Primary Office

Seattle Children's
OC.7.720 - Pulmonary
4800 Sand Point Way NE
Seattle, WA 98105
206-987-2174

Additional Offices

Seattle Children's Bellevue Clinic and Surgery Center
CB-11
1500 - 116th Ave NE
Bellevue, WA 98004
425-454-4644

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options